Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Steroid and Tacrolimus Avoidance Using NULOJIX® (Belatacept) in Renal Transplantation
NCT01856257Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2013
- Primary completion
- Apr 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of belatacept in kidney transplantation (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Estimated Glomerular Filtration Rate at 52 weeks. Started Jul 2013; status: terminated.
02
Drugs
belatacept
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT01856257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01856257.